60 Degrees Pharmaceuticals, Inc. Price & Performance (SXTP)

60 Degrees Pharmaceuticals has initiated a 1-for-5 reverse stock split, effective February 24, 2025, to fulfill Nasdaq's $1.00 minimum bid price requirement. This move consolidates every five shares into one while maintaining shareholder equity percentages. Despite revenue growth, the company faces financial hurdles, including significant cash burn and negative profit margins.123

60 Degrees Pharmaceuticals is broadening its clinical trial for Arakoda, originally FDA-approved for malaria prevention, to evaluate its efficacy against babesiosis, a tick-borne disease. Collaborations include Brigham and Women’s Hospital and other institutions. The trial, involving up to 33 patients, highlights the company's efforts to diversify its drug applications.145

60 Degrees Pharmaceuticals' stock hit a 52-week low of $0.42, reflecting an 87% annual decline. The company faces investor concerns over high cash burn and negative profit margins. Efforts to stabilize include a reverse stock split and clinical trials expansion, though market sentiment remains cautious.467